Evidence map›Paper›PMID 39421372›Full record

ArticleHeliyon2024

HI-Net: A novel histopathologic image segmentation model for metastatic breast cancer via lightweight dataset construction.

Fengze Li, Jieming Ma, Tianxi Wen, Zhongbei Tian, Hai-Ning Liang

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fengze LiUniversity of Liverpool, Liverpool, UK.
Jieming MaXi'an Jiaotong-Liverpool University, Suzhou, China.
Tianxi WenXi'an Jiaotong-Liverpool University, Suzhou, China.
Zhongbei TianUniversity of Liverpool, Liverpool, UK.
Hai-Ning LiangXi'an Jiaotong-Liverpool University, Suzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since 2020, breast cancer has remained the most prevalent cancer worldwide and the World Health Organisation projects significant increases by 2040, with new cases expected to exceed 3 million annually (a 40% increase) and deaths to surpass 1 million (a 50% increase), highlighting the urgent need for advancements in detection and treatment. Current detection of metastasis is highly dependent on labour-intensive and error-prone pathological examination of large-scale biotissue. Given the high-resolution (100,000 × 100,000 gigapixels) but limited quantity of open-source pathological slide datasets, existing deep learning models face preprocessing challenges. This paper introduces HI-Net, a high-speed panoramic feature-extraction pyramid network for rapid and accurate detection of metastatic breast cancer, balancing panoramic segmentation and local attention. Additionally, a lightweight pathological slide dataset optimised for 512 x 512-pixel resolution, derived from downsampled and reassembled competitive datasets, accelerates training and reduces computational costs. HI-Net demonstrates superior performance on existing medical imaging competition datasets and our lightweight dataset, evidencing its effectiveness across datasets and potential for contributing to the generalisation of intelligent diagnostics.

Indexed as

Breast cancerDeep learningHistopathology slideIntelligent diagnosisMedical imaging

Identifiers

PMID39421372
PMCPMC11483284

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.